WO2011030148A3 - Improvements in or relating to exfoliation - Google Patents

Improvements in or relating to exfoliation Download PDF

Info

Publication number
WO2011030148A3
WO2011030148A3 PCT/GB2010/051500 GB2010051500W WO2011030148A3 WO 2011030148 A3 WO2011030148 A3 WO 2011030148A3 GB 2010051500 W GB2010051500 W GB 2010051500W WO 2011030148 A3 WO2011030148 A3 WO 2011030148A3
Authority
WO
WIPO (PCT)
Prior art keywords
desmoglein
formulation
group
agents selected
exfoliation
Prior art date
Application number
PCT/GB2010/051500
Other languages
French (fr)
Other versions
WO2011030148A2 (en
Inventor
Anton Alexandroff
Original Assignee
X-Biocell Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by X-Biocell Limited filed Critical X-Biocell Limited
Publication of WO2011030148A2 publication Critical patent/WO2011030148A2/en
Publication of WO2011030148A3 publication Critical patent/WO2011030148A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/28—Rubbing or scrubbing compositions; Peeling or abrasive compositions; Containing exfoliants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Abstract

Disclosed is a formulation for use in the exfoliation of a mammalian subject, the formulation comprising: (i) one or more active agents selected from the group, (a), consisting of: a bacterial exfoliative toxin, or active derivative, analogue or truncated portion thereof; and/or (ii) one or more active agents selected from the group, (b), consisting of: a binding partner which binds to desmoglein 1, desmoglein 2, desmoglein 3 or desmoglein 4; and/or (iii) one or more active agents selected from the group, (c), consisting of: a binding partner which binds to laminin 5, laminin 6, integrin beta 4 subunit, collagen VII, collagen XVII, or Bullous Pemphigoid antigen 230 proteins; said active agent(s) being present in the formulation at a known concentration sufficient such that the formulation causes appropriate exfoliation of the subject's skin within a contact time in the range of 2 minutes to 1 hour; (iv) a cosmetically acceptable carrier, diluent or excipient.
PCT/GB2010/051500 2009-09-09 2010-09-08 Improvements in or relating to exfoliation WO2011030148A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0915732A GB2473432A (en) 2009-09-09 2009-09-09 Improvements in or relating to exfoliation
GB0915732.2 2009-09-09

Publications (2)

Publication Number Publication Date
WO2011030148A2 WO2011030148A2 (en) 2011-03-17
WO2011030148A3 true WO2011030148A3 (en) 2011-08-11

Family

ID=41203416

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2010/051500 WO2011030148A2 (en) 2009-09-09 2010-09-08 Improvements in or relating to exfoliation

Country Status (2)

Country Link
GB (1) GB2473432A (en)
WO (1) WO2011030148A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012149136A1 (en) 2011-04-26 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Production and delivery of a stable collagen
WO2017165502A1 (en) * 2016-03-22 2017-09-28 The General Hospital Corporation Compositions and methods for topical delivery of pharmaceutical agents
EP3469357A4 (en) * 2016-06-10 2020-04-22 NewSouth Innovations Pty Limited Diagnostic method
GB201819345D0 (en) 2018-11-28 2019-01-09 X Biocell Ltd Improvemets in or reating to biological exfoliation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654171A (en) * 1989-09-05 1997-08-05 Earth Chemical Company, Ltd. Polypeptide, process for preparing the same and pharmaceutical compositions and cosmetics containing the polypeptide
WO2000015300A1 (en) * 1998-09-16 2000-03-23 Ultra Cure Ltd. Method for peeling of epithelial tissue and apparatus and system for use therefor
JP2006006143A (en) * 2004-06-23 2006-01-12 Hiroshima Univ Method for diagnosing infectious impetigo and diagnostic kit therefor, and polypeptide and antibody to be used therefor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2925312B1 (en) * 2007-12-19 2016-12-02 Oreal COSMETIC USE OF DESMOGLEINE I PROTEINS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654171A (en) * 1989-09-05 1997-08-05 Earth Chemical Company, Ltd. Polypeptide, process for preparing the same and pharmaceutical compositions and cosmetics containing the polypeptide
WO2000015300A1 (en) * 1998-09-16 2000-03-23 Ultra Cure Ltd. Method for peeling of epithelial tissue and apparatus and system for use therefor
JP2006006143A (en) * 2004-06-23 2006-01-12 Hiroshima Univ Method for diagnosing infectious impetigo and diagnostic kit therefor, and polypeptide and antibody to be used therefor

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DANCER S J ET AL: "The epidermolytic toxins are serine proteases.", FEBS LETTERS 30 JUL 1990 LNKD- PUBMED:2384148, vol. 268, no. 1, 30 July 1990 (1990-07-30), pages 129 - 132, XP002629307, ISSN: 0014-5793 *
ISHII KEN ET AL: "Isolation of pathogenic monoclonal anti-desmoglein 1 human antibodies by phage display of pemphigus foliaceus autoantibodies.", THE JOURNAL OF INVESTIGATIVE DERMATOLOGY APR 2008 LNKD- PUBMED:18007588, vol. 128, no. 4, April 2008 (2008-04-01), pages 939 - 948, XP002629310, ISSN: 1523-1747 *
LADHANI SHAMEZ: "Understanding the mechanism of action of the exfoliative toxins of Staphylococcus aureus.", FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY 28 NOV 2003 LNKD- PUBMED:14625102, vol. 39, no. 2, 28 November 2003 (2003-11-28), pages 181 - 189, XP002629309, ISSN: 0928-8244 *
LAZAROVA Z ET AL: "Fab fragments directed against laminin 5 induce subepidermal blisters in neonatal mice.", CLINICAL IMMUNOLOGY (ORLANDO, FLA.) APR 2000 LNKD- PUBMED:10794429, vol. 95, no. 1 Pt 1, April 2000 (2000-04-01), pages 26 - 32, XP002629312, ISSN: 1521-6616 *
NISHIFUJI KOJI ET AL: "Staphylococcal exfoliative toxins: "molecular scissors" of bacteria that attack the cutaneous defense barrier in mammals.", JOURNAL OF DERMATOLOGICAL SCIENCE JAN 2008 LNKD- PUBMED:17582744, vol. 49, no. 1, January 2008 (2008-01-01), pages 21 - 31, XP002629308, ISSN: 0923-1811 *
PLANO L R ET AL: "Recombinant Staphylococcus aureus exfoliative toxins are not bacterial superantigens.", INFECTION AND IMMUNITY MAY 2000 LNKD- PUBMED:10769013, vol. 68, no. 5, May 2000 (2000-05-01), pages 3048 - 3052, XP002629306, ISSN: 0019-9567 *
WAHL JAMES K 3RD: "Generation of monoclonal antibodies specific for desmoglein family members.", HYBRIDOMA AND HYBRIDOMICS FEB 2002 LNKD- PUBMED:11991815, vol. 21, no. 1, February 2002 (2002-02-01), pages 37 - 44, XP002629311, ISSN: 1536-8599 *

Also Published As

Publication number Publication date
GB2473432A (en) 2011-03-16
WO2011030148A2 (en) 2011-03-17
GB0915732D0 (en) 2009-10-07

Similar Documents

Publication Publication Date Title
EP1855719A4 (en) Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus
HK1107030A1 (en) Oligopeptides for reducing elevated blood urea concentration
IL190693A (en) Agents for suppressing damage to transplanted islets after islet transplantation, which comprise an antibody that recognizes il-6 receptor and their use
NZ597692A (en) Anti-IGF antibodies
NZ595694A (en) Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
WO2008063279A3 (en) A stable composition comprising a bone anabolic protein, namely a pthrp analogue, and uses thereof
WO2005085422A8 (en) Adult stem cells and uses thereof
WO2008079290A3 (en) Stable buffered formulations containing polypeptides
WO2007120302A3 (en) Liquid crystalline substrates for culturing cells
WO2011030148A3 (en) Improvements in or relating to exfoliation
WO2006093857A3 (en) Method of providing readily available cellular material derived from peripheral blood and a composition thereof
MY166537A (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
MX338088B (en) 5imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes.
WO2008076819A3 (en) Human growth hormone formulations
UA102061C2 (en) Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
MX2010001723A (en) Formulations of antibodies and fc-fusion molecules using polycations.
CA2872275C (en) Stabilized formulations containing anti-dll4 antibodies
WO2009064366A3 (en) Methods and compositions for protein labeling using lipoic acid ligases
Abrol et al. Nanobacteria in the pathogenesis of urolithiasis: Myth or reality?
GB0620255D0 (en) Antibody and uses thereof
WO2007054537A8 (en) Novel bacterium and vaccine
WO2007113819A3 (en) Methods and compositions for preventing and treating streptococcus pneumoniae infection
WO2007098716A8 (en) Compounds analogous to growth hormone peptide secretagogues and preparations containing them
MX2007014803A (en) Cell nucleus-entering compositions.
EP1758923B8 (en) Peptide substance restoring myocardium function

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10754782

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10754782

Country of ref document: EP

Kind code of ref document: A2